WO2023118253 - CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS
National phase entry:
Publication Number
WO/2023/118253
Publication Date
29.06.2023
International Application No.
PCT/EP2022/087156
International Filing Date
21.12.2022
Title **
[English]
CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS
[French]
DÉRIVÉS D'ACIDE CYCLOHEXANE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DE LPA
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
ARMANI, Elisabetta
AMARI, Gabriele
PAGANO, Mafalda
GIULIANI, Marta
Priority Data
21217271.2
23.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3604 | |
| EPO | Filing, Examination, Granting | 14824 | |
| Japan | Filing, Examination, Granting | 2246 | |
| South Korea | Filing, Examination, Granting | 2166 | |
| USA | Filing, Examination, Granting | 8490 |
Total:
31,330
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.[French]
La présente invention concerne des composés de formule générale (I) inhibant le récepteur 1 de l'acide lysophosphatidique (LPA1), en particulier l'invention concerne des composés qui sont des dérivés d'acide cyclohexane, des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles dans le traitement de maladies ou d'états associés à une dysrégulation des récepteurs de LPA, en particulier la fibrose.